BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced that on October 2, 2025 its compensation committee approved inducement RSU grants to 11 new employees totaling 23,884 shares of common stock under the Amended and Restated 2019 Inducement Equity Plan.

Vesting: 25% of each award vests on November 16, 2026, then 1/12 of the remaining shares vest quarterly thereafter, contingent on continued employment. All awards were granted as inducements pursuant to Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted November 2019 and amended on Feb 10, 2023 and Dec 13, 2023.

PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restricted stock units for an aggregate of 23,884 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio

FAQ

What did BridgeBio (BBIO) announce on October 3, 2025 about inducement grants?

BridgeBio announced RSU inducement grants on October 2, 2025 totaling 23,884 shares to 11 new employees under Nasdaq Rule 5635(c)(4).

What is the vesting schedule for the BBIO inducement restricted stock units?

Each award vests 25% on Nov 16, 2026, then 1/12 of the remaining shares vest quarterly thereafter, subject to continued employment.

Under which plan were BridgeBio's (BBIO) October 2025 inducement awards granted?

The awards were granted under the Amended and Restated 2019 Inducement Equity Plan, amended on Feb 10, 2023 and Dec 13, 2023.

Do the BBIO inducement grants require shareholder approval under Nasdaq rules?

No immediate shareholder vote is required; the grants were made as inducements consistent with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement RSUs in BridgeBio's October 2025 grant?

A total of 11 new employees received restricted stock unit inducement grants.

Will BridgeBio's (BBIO) inducement grants cause material dilution to shareholders?

The press release states 23,884 shares were granted; it does not state total outstanding shares, so material dilution is not asserted in the release.